1364917-21-4

Basic information

• Product Name: 2,3,6-Trimethoxypyridine
• Synonyms: 2,3,6-Trimethoxypyridine
• CAS NO: 1364917-21-4
• Molecular Formula: C8H11NO3
• Molecular Weight: 169.17784
• Mol File: 1364917-21-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 219.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.093±0.06 g/cm3(Predicted)
• PKA: 0.63±0.10(Predicted)
• CAS DataBase Reference: 2,3,6-Trimethoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,6-Trimethoxypyridine(1364917-21-4)
• EPA Substance Registry System: 2,3,6-Trimethoxypyridine(1364917-21-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1364917-21-4(Hazardous Substances Data)

Usage

General Description

2,3,6-trimethoxypyridine is a chemical compound with the molecular formula C8H11NO3. It is a derivative of pyridine, with three methoxy (CH3O) groups attached to the 2, 3, and 6 positions of the pyridine ring. 2,3,6-trimethoxypyridine is commonly used in organic synthesis as a building block for the production of pharmaceuticals, pesticides, and other agrochemicals. It is also used as a flavoring agent in the food industry and has been studied for its potential medicinal properties, including its anti-inflammatory and anti-cancer effects. Additionally, 2,3,6-trimethoxypyridine has been investigated for its role in environmental applications, such as in the development of new materials or as a potential tool for the remediation of contaminated sites.

Upstream product

• 885963-28-0 3-hydroxy-2,6-dimethoxypyridine 
• 74-88-4 methyl iodide 
• 13445-16-4 3-bromo-2,6-dimethoxypyridine 

Relevant articles and documents

TBAJ-876, a 3,5-dialkoxypyridine analogue of bedaquiline, is active against Mycobacterium abscessus

Lung disease caused by Mycobacterium abscessus is very difficult to cure, and treatment failure rates are high. The antituberculosis drug bedaquiline (BDQ) is used as salvage therapy against this dreadful disease. However, BDQ is highly lipophilic, displays a long terminal half-life, and presents a cardiotoxicity liability associated with QT interval prolongation. Recent medicinal chemistry campaigns resulted in the discovery of 3,5-dialkoxypyridine analogues of BDQ which are less lipophilic, have higher clearance, and display lower cardiotoxic potential. TBAJ-876, a clinical development candidate of this series, shows attractive in vitro antitubercular activity and efficacy in a murine tuberculosis model. Here, we asked whether TBAJ-876 is active against M. abscessus. TBAJ-876 displayed submicromolar in vitro activity against reference strains representing the three subspecies of M. abscessus and against a collection of clinical isolates. Drug-drug potency interaction studies with commonly used anti-M. abscessus antibiotics showed no antagonistic effects, suggesting that TBAJ-876 could be coadministered with currently used drugs. Efficacy studies, employing a mouse model of M. abscessus infection, demonstrated potent activity in vivo. In summary, we demonstrate that TBAJ-876 shows attractive in vitro and in vivo activities against M. abscessus, similar to its BDQ parent. This suggests that next-generation BDQ, with improved tolerability and pharmacological profiles, may be useful for the treatment of M. abscessus lung disease in addition to the treatment of tuberculosis.